Journal of Leukocyte Biology Myeloid cells, immune suppression, tumor immunology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


A more recent version of this article appeared on January 1, 2006

Published online before print October 21, 2005
This Article
Right arrow Full Text (Reprint (PDF))
Right arrow All Versions of this Article:
jlb.0505271v1
79/1/140    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Murano, M.
Right arrow Articles by Tsiagbe, V. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Murano, M.
Right arrow Articles by Tsiagbe, V. K.
© by The Society for Leukocyte Biology
Journal of Leukocyte Biology, doi:10.1189/jlb.0505271


Received for publication May 17, 2005.
Revised August 5, 2005.
Accepted for publication August 17, 2005.


Article

Latent TGF-{beta}1-transduced CD4+ T cells suppress the progression of allergic encephalomyelitis

Mitsuyuki Murano *, Xiaozhong Xiong *, Naoko Murano *, James L. Salzer {dagger}, Juan J. Lafaille *, and Vincent K. Tsiagbe *@

Departments of *Pathology and NYU Cancer Institute and {dagger}Cell Biology, New York University School of Medicine, New York

@ To whom correspondence should be addressed. E-mail: tsiagv01{at}med.nyu.edu.


   Abstract

Systemic injection of small amounts of transforming growth factor-{beta} (TGF-{beta}), a cytokine produced by lymphoid and other cells, has a profound effect in protecting mice from the inflammatory demyelinating lesions of experimental allergic encephalomyelitis (EAE; an animal model for multiple sclerosis). However, TGF-{beta} has side-effects, which might be avoided if the cells producing TGF-{beta} can be delivered to the affected site in the nervous system to insure its local release in small amounts. Myelin basic protein (MBP)-specific, cloned CD4+ T cells were engineered by retroviral transduction to produce latent TGF-{beta}. Studies about the spontaneous form of EAE in T cell receptor (TCR)-transgenic recombination-activating gene (RAG)-1-/- mice showed that essentially all of the MBP-specific, TCR-transgenic RAG-1-/- (BALB/cxB10.PL)F1 mice develop spontaneous EAE by the age of 11 weeks. By 12 weeks, 25-50% of the mice have died from disease. A single injection of TGF-{beta}1-transduced T helper cell type 1 (Th1) cells significantly protected the mice from EAE, and untransduced Th1 cells did not protect. MBP-specific BALB/c Th2 clones, transduced with TGF-{beta}1-internal ribosome entry site-green fluorescent protein (GFP) significantly reduced EAE induction by untransduced Th1 cells in RAG-1-/- B10.PL mice. Furthermore, the GFP+ TGF-{beta}1-producing Th2 cells were detectable in the spinal cords of the injected mice.

Key Words: cytokines • gene therapy • multiple sclerosis







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2005 by the Society for Leukocyte Biology.